Trial Profile
A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs RVU 120 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Acronyms RIVER-51
- Sponsors Ryvu Therapeutics
- 29 Jan 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 29 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
- 29 Jan 2024 Status changed from recruiting to active, no longer recruiting.